Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Oct 29:6:69.
doi: 10.1186/s40560-018-0342-4. eCollection 2018.

Epidemiology, clinical characteristics, resistance, and treatment of infections by Candida auris

Andrea Cortegiani  1 , Giovanni Misseri  1 , Teresa Fasciana  2 , Anna Giammanco  2 , Antonino Giarratano  1 , Anuradha Chowdhary  3
Affiliations
Review

Epidemiology, clinical characteristics, resistance, and treatment of infections by Candida auris

Andrea Cortegiani et al. J Intensive Care. .

Abstract

Candida spp. infections are a major cause of morbidity and mortality in critically ill patients. Candida auris is an emerging multi-drug-resistant fungus that is rapidly spreading worldwide. Since the first reports in 2009, many isolates across five continents have been identified as agents of hospital-associated infections. Independent and simultaneous outbreaks of C. auris are becoming a major concern for healthcare and scientific community. Moreover, laboratory misidentification and multi-drug-resistant profiles, rarely observed for other non-albicans Candida species, result in difficult eradication and frequent therapeutic failures of C. auris infections. The aim of this review was to provide an updated and comprehensive report of the global spread of C. auris, focusing on clinical and microbiological characteristics, mechanisms of virulence and antifungal resistance, and efficacy of available control, preventive, and therapeutic strategies.

Keywords: Antifungal resistance; Antimicrobial resistance; C. auris; Candida; Candidemia; Invasive fungal infection.

PubMed Disclaimer

Conflict of interest statement

Not applicable.Not applicable.The authors declare that they have no competing interests.Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Phylogenetic tree obtained by neighbor-joining analysis of the D1-D2 region of genes encoding Candida auris 26S rRNA and correlated species
Fig. 2
Fig. 2
Timeline chart of C. auris reported cases. The reports from the European Centre for Diseases Prevention and Control (ECDC) and the Centers for Disease Control and Prevention are ongoing
Fig. 3
Fig. 3
Worldwide distribution of C. auris reported cases
See this image and copyright information in PMC

References

    1. Kullberg BJ, Arendrup MC. Invasive candidiasis. N Engl J Med. 2015;373:1445–1456. doi: 10.1056/NEJMra1315399. - DOI - PubMed
    1. Cortegiani A, Russotto V, Maggiore A, Attanasio M, Naro AR, Raineri SM, et al. Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients. Cochrane Database Syst Rev. 2016;1:CD004920. - PMC - PubMed
    1. Cortegiani A, Russotto V, Giarratano A. Associations of antifungal treatments with prevention of fungal infection in critically ill patients without neutropenia. JAMA. 2017;317:311–312. doi: 10.1001/jama.2016.16535. - DOI - PubMed
    1. Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62:e1–50. doi: 10.1093/cid/civ1194. - DOI - PMC - PubMed
    1. Cortegiani A, Russotto V, Raineri SM, Gregoretti C, De Rosa FG, Giarratano A. Untargeted antifungal treatment strategies for invasive candidiasis in non-neutropenic critically ill patients: current evidence and insights. Curr Fung Infect Rep. 2017;11:84–91. doi: 10.1007/s12281-017-0288-3. - DOI

LinkOut - more resources